Clinical Research

Vigil Neuroscience Inc.

Address
1 Broadway Suite 07-300

Sponsor Overview

assignment
1
sponsored trial
science
1
molecule
location_city
3
research centres
public
3
countries
person_search
3
investigators

Specializations

Leukoencephalopathy and adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)

Vigil Neuroscience Inc. is involved in clinical research focused on inherited white matter disorders, with particular attention to ALSP, a rare form of leukoencephalopathy affecting the central nervous system. The sponsor's clinical activity is centered on understanding disease-related neurological impairment in adults with this condition.

  • Central nervous system degeneration
  • White matter disease
  • Adult-onset neurodegenerative disorders

Its research interest in this area reflects a focus on rare neurological disease mechanisms and clinical outcomes relevant to patients with progressive brain pathology.

Neurology and rare disease therapeutics

The sponsor's clinical portfolio highlights work in neurology, especially conditions with limited treatment options and significant unmet medical need. The funded trial activity is directed toward therapeutic development for a rare neurogenetic disorder with prominent neurological manifestations.

  • Rare neurological disease
  • Neurogenetic conditions
  • Progressive neurologic impairment

This area of interest places emphasis on clinical evaluation of disease-specific neurological symptoms and functional decline in affected adults.

Inflammation-related microglial biology in brain disease

Vigil Neuroscience Inc. also shows interest in therapeutic targets linked to microglial function and neuroinflammatory processes within the brain. In the context of ALSP, this includes disease pathways associated with myeloid cell signaling and injury-related changes in the brain parenchyma.

  • Microglial activation
  • Neuroinflammation
  • Myeloid biology

These themes indicate a therapeutic interest in biological pathways that influence neuronal support, immune activity in the central nervous system, and progression of rare degenerative brain disorders.

Sponsored Trials

Trial Name Country Status
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)France FranceGermany GermanyThe Netherlands The NetherlandsNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 3 sites collaborated multiple times

This sponsor has worked with 3 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial
    165 other sponsors
  • 2.
    Nervous System Diseases1 trial
    449 other sponsors

Partnered Research Centres

3 centres
location_city
assignment680
Amsterdam UMC
Address
De Boelelaan 1117, 1081 HV Amsterdam
Learn morearrow_forward
location_city
assignment201
Hopitaux Universitaires Pitie Salpetriere
Address
47 Boulevard De L Hopital, 75651 Paris
Learn morearrow_forward
location_city
assignment433
Universitaet Leipzig
Address
Liebigstrasse 20, Zentrum-Suedost, 04103 Leipzig
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Vigil Neuroscience Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.